Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Irbesartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 3/20 | 0.74 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.74 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.74 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | EDNRA | P25101 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | HTR2B | P41595 | 1/20 | 0.74 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.74 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.74 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.74 |
| ▸ | ACHE | P22303 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irbesartan SCHEMBL4246 | 1.00 | AGTR1 (0.74) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| Irbesartan SCHEMBL3376730 | 0.99 | AGTR1 (0.73) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| Irbesartan SCHEMBL3098203 | 0.99 | AGTR1 (0.73) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| Irbesartan SCHEMBL4520818 | 0.99 | AGTR1 (0.73) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| Irbesartan SCHEMBL3373783 | 0.99 | AGTR1 (0.73) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| SCHEMBL683789 | 0.99 | AGTR1 (0.73) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| Irbesartan SCHEMBL2208976 | 0.99 | AGTR1 (0.73) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| Irbesartan SCHEMBL4726034 | 0.99 | AGTR1 (0.73) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| Irbesartan SCHEMBL4726870 | 0.99 | AGTR1 (0.73) | AGTR1LTB4R2ABCC3ABCC4ABCB11 | |
| SCHEMBL683876 | 0.99 | AGTR1 (0.73) | AGTR1LTB4R2ABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106390126-A | Pharmaceutical composition containing sartans and NEPi | 叶莉 | 2017-02-15 | — | — | CN | claimed |
| EP-2016073-B1 | PROCESS FOR THE PREPARATION OF PURE IRBESARTAN | LEK PHARMACEUTICALS (SI) | 2011-07-27 | — | — | EP | claimed |
| EP-2065035-B1 | Pharmaceutical formulations containing irbesartan | LESVI LABORATORIOS SL (ES) | 2010-07-21 | — | — | EP | claimed |
| CN-108348894-A | Ozonolysis for compound activation and ozonolysis | 空气交叉股份有限公司 | 2018-07-31 | — | — | CN | disclosed |
| CN-106390126-A | Pharmaceutical composition containing sartans and NEPi | 叶莉 | 2017-02-15 | — | — | CN | disclosed |
| EP-1799263-A4 | REDUCING ER STRESS IN THE TREATMENT OF OBESITY AND DIABETES | HARVARD COLLEGE (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1799263-A2 | REDUCING ER STRESS IN THE TREATMENT OF OBESITY AND DIABETES | The President and Fellows of Harvard College (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006097121-A1 | METHOD FOR PRODUCING BIPHENYL-TETRAZOLE COMPOUNDS | ULKAR KIMYA SANAYII VE TICARET A.S. (TR) | 2006-09-21 | — | — | WO | disclosed |
| US-20060160834-A1 | Combination therapy for the treatment of hypertension | MERCK & CO., INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006031931-A2 | REDUCING ER STRESS IN THE TREATMENT OF OBESITY AND DIABETES | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20040116510-A1 | Antihypertensive agent and cholesterol absorption inhibitor combination therapy | NICHTBERGER STEVEN A (US) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160834-A1 | Combination therapy for the treatment of hypertension | FABP4, GPR119, HMGCR | AGTR1 51/4885LTB4R2 849/4885ABCC3 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.